xMedica

NCT06531824ClinicalTrials.gov

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting…

שלב 3דרושים 11,000 משתתפים557 אתרים20 מדינות

קטגוריות

נפרולוגיה ואורולוגיה53%לב וכלי דם41%אנדוקריני ומטבולי4%מיילדות וגינקולוגיה2%

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2024-08-01; recorded start 2024-08-30
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 1218 other studies in this databaseCounted from the lead sponsor named in the record (Boehringer Ingelheim)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 480 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 11,000 participants (target), run at 557 sites, across 20 countries.

How this score is built
  • Enrolment38/40

    11,000 participants (target)

  • Site count25/25

    480 sites

  • Country count15/15

    20 countries

  • Planned duration9/10

    Planned over about 49 months

  • Sponsor scale10/10

    Boehringer Ingelheim has led 1,211 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.

מצבים רפואיים

  • Kidney Disease, Chronic

זכאות

מיןהכול
גילאים18 Years – ללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Key Inclusion Criteria: * Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires: 1. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR ≥20 \<45 mL/min/1.73m² (irrespective of diabetes status); or 2. No self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with urine albumin-to-creatinine ratio (uACR) ≥150 mg/g (or protein-to-creatinine ratio ≥225 mg/g); or 3. Self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with uACR ≥30 mg/g (or protein-to-creatinine ratio ≥45 mg/g). * Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate. Key Exclusion Criteria: * Blood potassium of \>5.2 mmol/L at screening visit * Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \>3x Upper Limit of Normal (ULN) at Screening visit (only one is required, with ALT preferred) * Known liver cirrhosis * On dialysis, functioning kidney transplant, or scheduled living donor transplant * Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days * Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor) * Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone) * Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

סוג המחקרהתערבותי
שלבשלב 3
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהQUADRUPLE (4)
גיוסדרושים 11,000 משתתפים

נותן חסות ושותפים

  • Boehringer Ingelheim נותן חסות

זרועות והתערבויות

  • Part 1: Run-in period (all participants)OTHER

    * Participant will receive empagliflozin (called Type E) together with study tablets (called Type F) prior to later randomisation to the main study treatment (Type M). * This run-in period allows empagliflozin to be established and have its effects on kidney function before randomisation, and to make sure participant can tolerate empagliflozin long-term. Participants will not routinely know whether type F treatment is active or inactive so that participants can become familiar with taking main study tablet (Type M) after randomization.

  • Part 2: Randomized treatment, follow-up period, treatment groupEXPERIMENTAL
  • Part 2: Follow-up period, placebo groupPLACEBO_COMPARATOR

התערבויות

  • תרופה BI 690517

    BI 690517 (called Type M randomized treatment)

  • תרופה Empagliflozin

    Empagliflozin (called Type E)

  • תרופה Placebo matching BI 690517

    Placebo matching BI 690517

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.

    Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization

    מסגרת זמן up to 4 years

  2. מדד תוצאה משני

    Key secondary outcome: Time to first event of kidney failure, hospitalization for heart failure or cardiovascular death

    מסגרת זמן up to 4 years

  3. מדד תוצאה משני

    Key secondary outcome: Time to first event of hospitalization for heart failure or cardiovascular death

    מסגרת זמן up to 4 years

  4. מדד תוצאה משני

    Key secondary outcome: Occurrences of hospitalizations from any cause (first and any subsequent, combined) or death from any cause

    מסגרת זמן up to 4 years

  5. מדד תוצאה משני

    Key secondary outcome: Time to death from any cause

    מסגרת זמן up to 4 years

  6. מדד תוצאה משני

    Key secondary outcome: Annual rate of change in eGFR from 1 month until last scheduled visit (i.e. chronic eGFR slope)

    מסגרת זמן up to 4 years

  7. מדד תוצאה משני

    Time to first event of kidney disease progression or cardiovascular death

    מסגרת זמן up to 4 years

תאריכים

תאריך התחלה30 באוגוסט 2024 (בפועל)
סיום ראשוני30 באוגוסט 2028 (משוער)
סיום30 באוגוסט 2028 (משוער)
פורסם לראשונה1 באוגוסט 2024 (בפועל)
עודכן לאחרונה17 בספטמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהספטמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

557 אתרים מגייסים

Argentina

מתקןעירמדינה או אזורמצב
Fundacion INTECNUSBarilocheמגייס
Terapia Renal DomiciliariaBuenos Airesמגייס
Centro de Salud Renal Junin SRLBuenos Airesמגייס
Dres. Iribarren & Asoc. ConsultarioBuenos Airesמגייס
Glenny Corp - Centro Medico SaavedraBuenos Airesמגייס
CPSIC SRL - Cardiologia PalermoCABAמגייס
Sanatorio Pasteur S.ACatamarcaמגייס
CEMICCiudad Autonoma Buenos Airesמגייס
CIMEL Chahin - Chahin S.A.Lanús Esteמגייס
Centro Nefrologico del MarMar del Plataמגייס
Mains BleuesRafaelaמגייס
Sanatorio Parque S.A.Rosarioמגייס
Hospital Privado de RosarioRosarioמגייס
Instituto de Nefrourologia y Nutricion de SaltaSaltaמגייס
Clinica El CastañoSan Juanמגייס
Centro de Investigaciones Medicas TucumanSan Miguel de Tucumánמגייס
Centro Integral de Medicina Respiratoria - CIMERSan Miguel de Tucumánמגייס
Instituto de Investigaciones Clinicas de RosarioSanta Feמגייס
CEREHA S.A.- Centro de Estudios Renales e Hipertension ArterialVilla Domínicoמגייס

Australia

מתקןעירמדינה או אזורמצב
Flinders Medical CentreBedford ParkSouth Australiaמגייס
Eastern Health-Box Hill HospitalBox HillVictoriaמגייס
Renal Research, GosfordGosfordNew South Walesמגייס
Austin HealthHeidelberg HeightsVictoriaמגייס
St George HospitalKogarahNew South Walesמגייס
Liverpool HospitalLiverpoolNew South Walesמגייס
The Alfred HospitalMelbourneVictoriaמגייס
St Vincent's Hospital MelbourneMelbourneVictoriaמגייס
Macquarie UniversityNew South Walesמגייס
Westmead HospitalNew South Walesמגייס
Hervey Bay HospitalPialbaQueenslandמגייס
Port Macquarie Base Hospital (PMBH)Port MacquarieNew South Walesמגייס
Griffith UniversitySouthportQueenslandמגייס
Sunshine HospitalSt AlbansVictoriaמגייס
Toowoomba HospitalToowoombaQueenslandמגייס

Belgium

מתקןעירמדינה או אזורמצב
AZ Sint-Jan BruggeBrugesמגייס
Ziekenhuis Oost-LimburgGenkמגייס
UZ BrusselJetteמגייס
Centre Hospitalier Universitaire de LiègeLiègeמגייס

Brazil

מתקןעירמדינה או אזורמצב
Centro de Pesquisa Clínica do CoraçãoAracajuמגייס
Santa Casa de Belo HorizonteBelo Horizonteמגייס
Centro de Pesquisa do Hospital Evangelico de Belo HorizonteBelo Horizonteמגייס
Universidade Estadual Paulista "Julio De Mesquita Filho"Botucatuמגייס
Hospital Universitário São Francisco na Providência de DeusBragança Paulistaמגייס
CEG - Centro de Endocrinologia GelonezeCampinasמגייס
Instituto Cardiovascular de Linhares LtdaCentro Linharesמגייס
PUC Trials - Núcleo de Pesquisa Clínica da Escola de Medicina da PUC-PRCuritibaמגייס
Hospital Universitário Walter Cantídio - UFCFortalezaמגייס
Centro de Pesquisas em Diabetes e Doencas MetabolicasFortalezaמגייס
Hospital Ruy AzeredoGoiâniaמגייס
Clínica CENDI Endocrinologia e DiabetesGoiâniaמגייס

507 אתרים נוספים מצוינים ברשומת המרשם.

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 17 בספטמבר 2026

    אתר נוסף

    37 sites added (557 total)

    520557

  2. 2 בספטמבר 2026

    אתר נוסף

    5 sites added (520 total)

    515520

  3. 21 באוגוסט 2026

    אתר נוסף

    18 sites added (515 total)

    497515

  4. 10 באוגוסט 2026

    אתר נוסף

    17 sites added (497 total)

    480497

מרשם: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06531824